Human Antibodies Neutralize Avian Flu

Human Antibodies Neutralize Avian Flu
A recent study conducted at the Burnham Institute for Medical Research in California, led by Professor Robert Liddington, showed that human antibodies can neutralize the effect of the avian flu virus. These antibodies can be used to generate vaccines and treatments for a large variety of influenza viruses.
Professor Robert Liddington (Credit: Burnham Institute for Medical Research) 
Professor Robert Liddington
(Credit: Burnham Institute
for Medical Research)

Influenza pandemics are worldwide outbreaks of disease that occur when a new influenza virus emerges for which people have little or no immunity. The disease spreads very quickly; moving from person to person and can affect whole countries. Many health professionals are concerned that the spread of avian flu throughout eastern Asia presents a significant threat to human health. Worldwide, more than 250,000 deaths from seasonal influenza occur annually. Current treatment methods include vaccines which have to be updated yearly and anti-viral medications which only have limited effectiveness.

Researchers at the Dana-Farber Cancer Institute, Burnham Institute for Medical Research, and the Centers for Disease Control and Prevention have discovered that monoclonal antibodies (mAb) neutralize an unprecedented range of influenza A viruses, including avian influenza A (H5N1) virus, previous pandemic influenza viruses, and some seasonal influenza viruses. The team identified antibodies that neutralize a broad range of influenza A subtypes. The antibodies bind to a highly conserved stem area in the H5 type hemagglutinin (HA). Once they bind to the stem, the virus cannot change to a conformation, which is necessary in order to enter the host cell. This prevents further infection of host cells and the proliferation of virus mutants. The research showed that a great number of different types of bird flu were inhibited by the mAb and that mAbs protected mice that were exposed to the H5N1 virus even when injected three days after the infection. 

 Crystal structure of influenza hemagglutinin H5 bound to a potent antibody (F10, in red) capable of neutralizing more than half of all strains of influenza virus (Credit: Burnham Institute)
Crystal structure of influenza
hemagglutinin H5 bound to a potent
antibody (F10, in red) capable of neutralizing
more than half of all strains of
influenza virus (Credit: Burnham Institute)

“The head portion of hemagglutinin is highly mutable, leading to the rise of forms of the virus that can evade neutralizing antibodies,” said Robert Liddington, Ph.D, one of the investigators on the study. “However, the stem region of hemagglutinin is highly conserved because it undergoes a dramatic conformational change to allow entry of viral RNA into the host cell. It’s very difficult to get a mutation that doesn’t destroy that function, which explains why we aren’t seeing escape mutants and why these antibodies neutralize such a variety of strains of influenza.”

Therapeutic antibodies are more expensive to produce than existing influenza drugs; however, they can be easily manufactured and stockpiled. In an event of an outbreak, these antibodies can be used in combination with antiviral treatments and contain the pandemic while the vaccination is being developed. The scientists say that these antibodies can be used for both the prevention and early treatment of influenza infection. Risk groups, such as medical personnel and individuals with preexisting conditions, could benefit most from this new type of treatment.
 
TFOT has previously covered the production of a vaccination for the H7N1 flu strain by a European consortium of researchers. More recently, we have brought you the new vaccination for meningitis B, developed by Novartis, an international drug company.
 
More information on the antibodies research, can be found on the Burnham Institute for Medical Research website.
email
Share This
Don't be shellfish...Facebook0Twitter0Google+0StumbleUpon0DiggReddit0Email

About the author

Anni Shaer Levitt

Anni has a B.Sc. in Psychology and Biology from the Hebrew University and is currently working on her M.Sc in Neurobiology. Her thesis will focus on face perception and processing.

View all articles by Anni Shaer Levitt